{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:21:09Z","timestamp":1793845269953,"version":"4.6.1"},"reference-count":16,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib\/melphalan\/prednisone (ALCYONE) or lenalidomide\/dexamethasone (Rd; MAIA) versus standard-of-care regimens for transplant-ineligible newly diagnosed multiple myeloma. In these studies, patients could switch from DARA IV to subcutaneous daratumumab (DARA SC) while receiving daratumumab monotherapy in ALCYONE (as of Cycle 11) or daratumumab plus Rd in MAIA. The phase 3 COLUMBA study demonstrated noninferiority of DARA SC to DARA IV. DARA SC reduced administration time, allowing patients to spend less time in healthcare settings, a relevant practical consideration for patient care in the COVID-19 pandemic\/settings of limited healthcare resources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DARA SC 1800\u2005mg was administered every 4 weeks, per approved dosing schedules. We evaluated safety and patient-reported experience (ALCYONE only) among patients who switched from DARA IV to DARA SC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-seven patients in ALCYONE and 135 in MAIA switched to DARA SC. Three (2.2%; MAIA) patients reported injection-site reactions, all of which were mild. No infusion-related reactions occurred with DARA SC. In ALCYONE, &gt;80% of patients preferred DARA SC over DARA IV. Grade 3\/4 treatment-emergent adverse events (TEAEs) occurred in 5.3% of patients in ALCYONE and 25.9% in MAIA; one (0.7%; MAIA) patient experienced a TEAE with an outcome of death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For transplant-ineligible newly diagnosed multiple myeloma, DARA SC (monotherapy\/with Rd) was safe and preferred over DARA IV. ClinicalTrials.gov, NCT02195479\/NCT02252172.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221103551","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T12:44:22Z","timestamp":1662468262000},"page":"1172-1177","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"first","affiliation":[{"name":"University Hospital of Salamanca\/IBSAL\/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Rigaudeau","sequence":"additional","affiliation":[{"name":"H\u00f4pital Andre Mignot, Service d\u2019Hematologie et d\u2019Oncologie, Le Chesnay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supratik","family":"Basu","sequence":"additional","affiliation":[{"name":"Royal Wolverhampton Hospitals NHS Trust and University, Wolverhampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[{"name":"Clinical Department of Haematology, 1st Medical Department, Charles University in Prague, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Schots","sequence":"additional","affiliation":[{"name":"UZ Brussel-VUB, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wrobel","sequence":"additional","affiliation":[{"name":"Uniwersytet Medyczny we Wroc\u0142awiu, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine S","family":"Gries","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupa","family":"Kudva","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Tromp","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rian","family":"Van Rampelbergh","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Pei","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Titusville, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wroblewski","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Delioukina","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[{"name":"Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"bibr1-10781552221103551","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"bibr2-10781552221103551","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3474.3474"},{"key":"bibr3-10781552221103551","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"bibr4-10781552221103551","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351"},{"key":"bibr5-10781552221103551","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"bibr6-10781552221103551","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23693"},{"key":"bibr7-10781552221103551","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0855-4"},{"key":"bibr8-10781552221103551","volume-title":"DARZALEX\u00ae (daratumumab) injection, for intravenous use [package insert]","author":"DARZALEX","year":"2022"},{"key":"bibr9-10781552221103551","unstructured":"European Medicines Agency. DARZALEX 20\u2005mg\/mL concentrate for solution for infusion. Summary of Product Characteristics, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004077\/WC500207296.pdf (accessed 7 May 2021)."},{"key":"bibr10-10781552221103551","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243790"},{"key":"bibr11-10781552221103551","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3"},{"key":"bibr12-10781552221103551","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16980"},{"key":"bibr13-10781552221103551","volume-title":"DARZALEX FASPRO\u2122 (daratumumab and hyaluronidase-fihj) [package insert]","author":"DARZALEX FASPRO","year":"2022"},{"key":"bibr14-10781552221103551","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30124-1"},{"key":"bibr15-10781552221103551","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"bibr16-10781552221103551","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221103551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221103551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221103551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:04Z","timestamp":1777688824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221103551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1177\/10781552221103551"],"URL":"https:\/\/doi.org\/10.1177\/10781552221103551","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]}}}